Month: January 2023

NORCROSS, Ga., Jan. 05, 2023 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, announced today that in late December 2022, it ended enrollment of NAVIGATE, its seamless, more...

Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into Phase 1 clinical trials in more...

Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh PR Newswire Technologies Licensed from University of Pittsburgh May Have the Potential to Provide Long-Term Efficacy and to Change the Course of more...

CTI BioPharma to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire SEATTLE , Jan. 5, 2023 /PRNewswire/ — CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will present a corporate overview at more...

– Topline data for Phase 2 DAVIO 2 clinical trial in wet AMD expected in 4Q 2023 – – Enrollment remains on-track in Phase 2 DAVIO 2 clinical trial for wet AMD and Phase 2 more...

DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, more...

NEW YORK, NY / ACCESSWIRE / January 5, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary more...